Recent Developments, Liquidity and Management’s Plans (Details Narrative) |
3 Months Ended | 4 Months Ended | 6 Months Ended | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Apr. 16, 2021
USD ($)
shares
|
Apr. 16, 2021
USD ($)
shares
|
Jun. 30, 2021
USD ($)
|
Mar. 31, 2021
USD ($)
|
Jun. 30, 2020
USD ($)
|
Mar. 31, 2020
USD ($)
|
Apr. 15, 2021
shares
|
Jun. 30, 2021
USD ($)
Integer
$ / shares
shares
|
Jun. 30, 2020
USD ($)
|
Dec. 31, 2020
USD ($)
|
Mar. 23, 2020 |
Dec. 31, 2019
USD ($)
|
Dec. 29, 2019
USD ($)
|
|
| Multiemployer Plan [Line Items] | |||||||||||||
| Cash and Cash Equivalents, at Carrying Value | $ 2,127,372 | $ 2,127,372 | $ 148,284 | ||||||||||
| [custom:DescriptionOfContributionTransaction] | cause Cystron to contribute substantially all of the assets associated with its business or developing and manufacturing Cystron’s COVID-19 vaccine candidate to Oravax. In consideration for the Company’s commitment to consummate the Contribution Transaction, Oravax issued to the Company | ||||||||||||
| Royalty payments, percentage | 0.025 | ||||||||||||
| Accounts Payable, Current | 3,298,637 | 3,298,637 | 1,801,729 | ||||||||||
| Amounts paid by related party | 3,062,444 | ||||||||||||
| Goodwill | 10,498,539 | $ 10,498,539 | |||||||||||
| Shares issued for acquistion | shares | 8,335,627 | ||||||||||||
| Debt Instrument, Convertible, Threshold Consecutive Trading Days | Integer | 10 | ||||||||||||
| Debt Instrument, Redemption, Description | Milestone Shares to be issued be deemed to be less than $5.00 per share | ||||||||||||
| Marketable Securities, Current | 19,503,001 | $ 19,503,001 | |||||||||||
| Loss Before Income Tax | 18,092,336 | $ 1,094,909 | 21,182,040 | 2,076,858 | |||||||||
| Working capital | 19,026,775 | 19,026,775 | |||||||||||
| Stockholder's equity | 31,074,335 | $ (8,346,738) | (3,051,439) | $ (2,664,780) | 31,074,335 | (3,051,439) | (5,257,034) | $ (2,332,831.00) | $ (1,726,363) | ||||
| Accumulated deficit | 69,854,565 | 69,854,565 | $ 48,672,525 | ||||||||||
| Net cash used by operating activities | 8,258,496 | 2,130,087 | |||||||||||
| Net loss | 18,092,336 | $ 3,089,704 | $ 1,094,909 | $ 981,949 | 21,182,040 | 2,076,858 | |||||||
| Decrease in trade and other payables | 1,988,204 | $ 454,951 | |||||||||||
| Share based compensation | $ (15,036,051) | ||||||||||||
| MyMD Pharmaceuticals (Florida), Inc [Member] | |||||||||||||
| Multiemployer Plan [Line Items] | |||||||||||||
| Shares issued for acquistion | shares | 32,741,622 | ||||||||||||
| Restricted Stock Units (RSUs) [Member] | |||||||||||||
| Multiemployer Plan [Line Items] | |||||||||||||
| Shares vested | shares | 394,680 | 263,026 | |||||||||||
| Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value | $ / shares | $ 4.94 | ||||||||||||
| Oravax [Member] | |||||||||||||
| Multiemployer Plan [Line Items] | |||||||||||||
| Accounts Payable, Current | 1,500,000 | $ 1,500,000 | |||||||||||
| Premas [Member] | |||||||||||||
| Multiemployer Plan [Line Items] | |||||||||||||
| Accounts Payable, Current | 300,000 | 300,000 | |||||||||||
| Contribution Agreement [Member] | |||||||||||||
| Multiemployer Plan [Line Items] | |||||||||||||
| Cash and Cash Equivalents, at Carrying Value | $ 1,500,000 | $ 1,500,000 | |||||||||||
| Common Stock, Capital Shares Reserved for Future Issuance | shares | 390,000 | 390,000 | |||||||||||
| Contribution Agreement [Member] | Premas Biotech PVT Ltd. [Member] | |||||||||||||
| Multiemployer Plan [Line Items] | |||||||||||||
| Due to related parties | $ 1,500,000 | 1,500,000 | |||||||||||
| Contribution Agreement [Member] | Pre-merger Akers Biosciences, Inc. [Member] | |||||||||||||
| Multiemployer Plan [Line Items] | |||||||||||||
| Amounts paid by related party | $ 1,200,000 | ||||||||||||
| Merger Agreement [Member] | |||||||||||||
| Multiemployer Plan [Line Items] | |||||||||||||
| Issuance of post reverse stock split | shares | 28,553,307 | ||||||||||||
| Exchange ratio percentage | 77.05% | ||||||||||||
| Percentage of common stock | 49.68% | 49.68% | |||||||||||
| Merger Agreement [Member] | Pre-funded Warrants [Member] | |||||||||||||
| Multiemployer Plan [Line Items] | |||||||||||||
| Warrants to purchase | shares | 986,486 | 986,486 | |||||||||||
| Cystron Biotech LLC [Member] | Membership Interest Purchase Agreement [Member] | |||||||||||||
| Multiemployer Plan [Line Items] | |||||||||||||
| Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage | 100.00% | ||||||||||||
| MYMD Pharmaceuticals, Inc., [Member] | Merger Agreement [Member] | |||||||||||||
| Multiemployer Plan [Line Items] | |||||||||||||
| Business acquisition description | Upon completion of the Merger and the transactions contemplated in the Merger Agreement, the Company issued 28,553,307 post reverse stock split shares of Company Common Stock to the former stakeholders of pre-Merger MyMD Florida at the Exchange Ratio. Upon completion of the Merger and the transactions contemplated in the Merger Agreement, the former stakeholders of pre-Merger MyMD Florida held approximately 77.05% of the Company’s Common Stock outstanding on a fully diluted basis, assuming the exercise in full of the pre-funded warrants to purchase 986,486 shares of Company Common Stock and including 4,188,315 shares of Company Common Stock underlying options to purchase shares of pre-Merger MyMD Florida Common Stock assumed by the company at closing and after adjustments based on the Company’s net cash at closing. Holders of pre-Merger common stock of the Company held approximately 22.95% of the outstanding equity of the Company. Also upon completion of the Merger and the transactions contemplated by the Merger Agreement, the Company assumed 4,188,315 MyMD Florida stock options subject to certain terms contained in the Merger Agreement (including, but not limited to, the amendment of such stock option to extend the term of such stock option for a period expiring on April 16, 2023, the second-year anniversary of the Merger. | ||||||||||||
| Akers Biosciences, Inc [Member] | |||||||||||||
| Multiemployer Plan [Line Items] | |||||||||||||
| Business acquisition description | Akers’ valuation is based upon 8,335,627 common shares outstanding and 263,026 vested restricted stock units (“RSU’) with a fair market value of $4.94 per share, the closing price of Akers common shares on the NASDAQ Stock Exchange on April 16, 2021. | ||||||||||||
| Goodwill | $ 10,498,539 | $ 10,498,539 | |||||||||||
| Pre market capitalization | 42,477,346 | 42,477,346 | |||||||||||
| Tangible asset | $ 31,978,807 | $ 31,978,807 | |||||||||||